<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00179465</url>
  </required_header>
  <id_info>
    <org_study_id>2004P000078</org_study_id>
    <nct_id>NCT00179465</nct_id>
  </id_info>
  <brief_title>Treating Schizophrenia by Correcting Abnormal Brain Development</brief_title>
  <official_title>Addition of Tiagabine to Second-Generation Antipsychotics in the Treatment of Recent-Onset Schizophrenia by Modification of Developmental Reorganization of the Prefrontal Cortex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment with tiagabine (Gabitril) during&#xD;
      the early course of schizophrenia can fundamentally correct the brain deficits associated&#xD;
      with the disease.&#xD;
&#xD;
      This study is funded by the National Institutes of Health.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is hypothesized that enhancement of GABA neurotransmission during the early course of the&#xD;
      illness by tiagabine (Gabitril), a GABA transporter GAT-1-specific inhibitor and a&#xD;
      FDA-approved anticonvulsant, will improve both clinical symptoms and working memory in&#xD;
      schizophrenia. This improvement is postulated to be the result of tiagabine-mediated&#xD;
      modification of the developmental synaptic pruning of prefrontal cortical circuitry. The&#xD;
      occurrence of circuitry modification after tiagabine treatment will be assessed by the&#xD;
      following independent methodologic approaches: MRI morphometric analysis of prefrontal gray&#xD;
      matter volume and fMRI measurements of brain activity patterns during performance of tasks&#xD;
      that probe working memory.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2003</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurocognitive Functions-Working Memory</measure>
    <time_frame>Working memory will be assessed at baseline and at 6-month time point to see if working memory changes after 6 months compared to baseline measurement</time_frame>
    <description>Working memory will be assessed using the n-back working memory test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurocognitive Functions-Executive Function</measure>
    <time_frame>Executive function will be assessed at baseline and at 6-month time point to see if executive function changes after 6 months compared to baseline measure</time_frame>
    <description>Executive function, which is a complex form of working memory, will be assessed using the MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) battery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical symptoms</measure>
    <time_frame>Symptoms will be assessed at baseline and at 6-month time point to see if symptoms change after 6 months compared to baseline measures</time_frame>
    <description>Positive and negative symptoms will be quantified using PANSS (positive and negative symptom scale)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Antipsychotic plus study drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half of the subjects will receive the study medications in addition to their ongoing antipsychotic regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antipsychotics plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Half of the subjects will receive placebo in addition to their antipsychotic regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiagabine</intervention_name>
    <description>Up to 36 mg daily</description>
    <arm_group_label>Antipsychotic plus study drug</arm_group_label>
    <other_name>Antipsychotic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Antipsychotics plus placebo</arm_group_label>
    <other_name>Antipsychotic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meets criteria for the diagnosis of schizophrenia, with onset of psychotic symptoms&#xD;
             within the past 3 years.&#xD;
&#xD;
          -  Currently on second-generation antipsychotics for at least 3 months.&#xD;
&#xD;
          -  Age 18-25, otherwise healthy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of schizoaffective disorder.&#xD;
&#xD;
          -  Has failed two or more clinically adequate antipsychotic trials.&#xD;
&#xD;
          -  History of seizures or any neurologic disorders.&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
&#xD;
          -  Known HIV infection.&#xD;
&#xD;
          -  Actively suicidal.&#xD;
&#xD;
          -  History of any substance dependence.&#xD;
&#xD;
          -  Currently meets criteria for substance abuse/dependence.&#xD;
&#xD;
          -  Other MRI exclusion criteria per Radiology Department protocols.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>T.-U. Wilson Woo, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center, Harvard Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Woo TU, Crowell AL. Targeting synapses and myelin in the prevention of schizophrenia. Schizophr Res. 2005 Mar 1;73(2-3):193-207. Review.</citation>
    <PMID>15653262</PMID>
  </reference>
  <reference>
    <citation>Woo TU, Whitehead RE, Melchitzky DS, Lewis DA. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5341-6.</citation>
    <PMID>9560277</PMID>
  </reference>
  <reference>
    <citation>Woo, TUW, Spencer KS, McCarley RW. Gamma oscillations and the early course and progression of schizophrenia. Harvard Review of Psychiatry 2009.</citation>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Tsung-Ung Wilson Woo</investigator_full_name>
    <investigator_title>Assistant Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Treatment</keyword>
  <keyword>fMRI</keyword>
  <keyword>Cognition</keyword>
  <keyword>Brain development</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiagabine</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

